BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

News Release

BioDelivery Sciences to Hold Analyst and Investor Day to Discuss BELBUCA® Commercialization Plans on February 1st in New York City

January 26, 2017 at 12:00 AM EST

RALEIGH, N.C., Jan. 26, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will host an event for analysts and investors from 12:00 PM – 2:30 PM Eastern Time on Wednesday, February 1st, 2017, in New York City, to discuss BELBUCA® (buprenorphine) buccal film (CIII) and plans for the commercialization of BELBUCA, as well as BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII).  The event follows the closing of BDSI's previously announced agreement with Endo Pharmaceuticals, Inc. (Endo), which transferred the worldwide rights to BELBUCA back to BDSI.

The event will feature Sanford M. Silverman, M.D., Medical Director and CEO, Comprehensive Pain Medicine, Pompano Beach, FL; Assistant Professor of Medicine, University of Miami, Miller School of Medicine; and Affiliate Assistant Professor of Clinical Biomedical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL.  Dr. Silverman will discuss the current and future role of opioids, including BELBUCA, in the treatment of chronic pain.  Also, members of BDSI's management team will discuss commercial and business development plans for BELBUCA. 

A live webcast of the event will be available at and on the BDSI website at  The live event is intended for institutional investors and sell-side analysts.  Please contact Mac MacDonald at 212-915-2567 or via e-mail at for more information. 

Presenter Biography

Sanford M. Silverman, MD, is in private practice as the Medical Director and CEO of Comprehensive Pain Medicine in Pompano Beach, FL. He is board certified in anesthesiology with added qualifications in pain management from the American Board of Anesthesiology and Diplomate from both the American Board of Pain Medicine and the American Board of Addiction Medicine. He is also an Assistant Professor of Medicine at the University of Miami, Miller School of Medicine and an Affiliate Assistant Professor of Clinical Biomedical Science at Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton FL.

Dr. Silverman's practice consists of interventional and medical treatment of chronic pain and opioid addiction, and his current interests include treating complex chronic pain with hyperalgesia. His other areas of expertise include interventional pain management, controlled substance management and addiction issues, and prescription drug abuse.

Dr. Silverman currently serves on the board of the American Society of Interventional Pain Physicians (ASIPP) as a Director-at-Large. He is also a member of the American Society of Regional Anesthesia, American Academy of Pain Medicine, and American Society of Addiction Medicine.  Dr. Silverman has authored numerous articles in publications such as Anesthesiology, the Journal of Cardiothoracic and Vascular Anesthesia, the Canadian Journal of Anesthesiology, and Pain Physician. He was involved in developing the CDC opioid guidelines representing ASIPP.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine.  BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's development strategy focuses on the utilization of the FDA's 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.

BDSI's area of focus is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs.  BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence.  BDSI's headquarters is in Raleigh, North Carolina.  

For more information, please visit or follow us:

Twitter:             @BioDeliverySI

BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and BELBUCA® (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences.   ONSOLIS® (fentanyl buccal soluble film) (CII) is licensed in the U.S. to Collegium Pharmaceutical pursuant to the U.S. licensing and development agreement between BDSI and Collegium. For full prescribing information and important safety information on BDSI products, including BOXED WARNINGS for ONSOLIS, please visit where the Company promptly posts press releases, SEC filings and other important information or contact the Company at (800) 469-0261.  For full prescribing and safety information on BELBUCA, please visit and for full prescribing and safety information on BUNAVAIL, please visit

Cautionary Note on Forward-Looking Statements

This press release, the presentation described herein, and any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, the results of the Company's reacquisition of, and commercialization efforts for BELBUCA as described herein) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

BDSI®, BEMA®, ONSOLIS® and BUNAVAIL® are registered trademarks of BioDelivery Sciences International, Inc.  The BioDelivery Sciences and BUNAVAIL logos are trademarks owned by BioDelivery Sciences International, Inc.  BELBUCA® is a trademark currently owned by Endo Pharmaceuticals.  All other trademarks and tradenames are owned by their respective owners.

© 2016 BioDelivery Sciences International, Inc.  All rights reserved.

SOURCE BioDelivery Sciences International, Inc.

For further information: Investors: Matthew P. Duffy, Managing Director, LifeSci Advisors, LLC, 212-915-0685,, or Al Medwar, Senior Vice President, Corporate and Business Development, BioDelivery Sciences International, Inc., 919-582-9050,; Media: Susan Forman/Laura Radocaj, Dian Griesel Int'l., 212-825-3210,,